Cost-effective osteoporosis treatment thresholds in Greece

Osteoporos Int. 2015 Jul;26(7):1949-57. doi: 10.1007/s00198-015-3055-8. Epub 2015 Mar 5.

Abstract

A Greek-specific cost-effectiveness analysis determined the FRAX-based intervention thresholds. Assuming a willingness to pay of 30,000 <euro>, osteoporosis treatment is cost-effective in subjects under the age of 75 with 10-year probabilities for hip and major osteoporotic fractures of 2.5 and 10 %, respectively, while for older patients, the same thresholds are raised to 5 and 15 %.

Introduction: The purpose of this study was to determine the FRAX calculated fracture probabilities at which therapeutic intervention can be considered as cost-effective in the Greek setting.

Methods: A Markov cohort model was populated with Greek data, and quality-adjusted life years (QALYs) were used to calculate the cost-effective thresholds for an annual medication cost of 733.7 <euro> by gender and age. Average FRAX-based 10-year probabilities for both major osteoporotic and hip fractures were multiplied by the model-derived relative risk at which a cost of 30,000 <euro> for each QALY gained was observed for treatment versus to no intervention.

Results: A biphasic intervention threshold model is supported by our findings. Osteoporosis treatment becomes cost-effective when absolute 10-year probabilities for hip and major osteoporotic fractures reach 2.5 and 10 %, respectively, among both men and women under the age of 75. For older subjects, the proposed intervention thresholds are raised to 5 and 15 % 10-year probability for hip and major osteoporotic fractures, respectively.

Conclusions: Cost-effective osteoporosis treatment may be facilitated in Greece if FRAX algorithm is used to identify subjects with 10-year probabilities for hip and major osteoporotic fractures of 2.5 and 10 %, under the age of 75, while for older patients, the relevant thresholds are 5 and 15 %, respectively.

MeSH terms

  • Age Factors
  • Aged
  • Aged, 80 and over
  • Bone Density Conservation Agents / economics
  • Bone Density Conservation Agents / therapeutic use*
  • Cost-Benefit Analysis
  • Drug Costs / statistics & numerical data
  • Female
  • Greece / epidemiology
  • Health Care Costs / statistics & numerical data
  • Hip Fractures / economics
  • Hip Fractures / epidemiology
  • Hip Fractures / prevention & control
  • Humans
  • Male
  • Middle Aged
  • Models, Econometric
  • Osteoporosis / drug therapy
  • Osteoporosis / economics*
  • Osteoporosis / epidemiology
  • Osteoporotic Fractures / economics*
  • Osteoporotic Fractures / epidemiology
  • Osteoporotic Fractures / prevention & control
  • Risk Assessment / methods
  • Sex Factors

Substances

  • Bone Density Conservation Agents